Pembrolizumab

帕博利珠单抗

Report date: 2026/05/23 20:00:57
First In Class

Base Information

Drug NamePembrolizumab
Drug Alias Name喷洛利珠单抗Pembrolizumabum匹博利组单抗Humanised monoclonal IgG4 antibody against PD-1Anti-PD-1 monoclonal antibody (MSD) +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUveal melanomaBone metastasesRespiratory papillomatosis +[169] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaMelanoma
Original Approved Country/TerritoryUnited States
Original Approved Date2014/09/04
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[59] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesLepu Medical Technology (Beijing) Co LtdDana-Farber Cancer InstituteIstituti Clinici Scientifici Maugeri Spa +[79] 
Inactive CompaniesWuhan Binhui Biotechnology Co LtdUtah State UniversityMsd (Merck Sharp & Dohme) Ireland (Carlow) +[45] 
Active IndicationsUveal melanomaBone metastasesRespiratory papillomatosis +[142] 
Inactive IndicationsMedullary thyroid cancer (MTC)Penile Squamous Cell CarcinomaRichter's Syndrome +[27] 

Other Information

ATC CodeL01XC18
Related LinksWikipediaDrugBankKEGG